Program
voclosporin
Also written as “LX211”, “Voclosporin” and “LUPKYNIS”.
Its studies are mostly in Lupus Nephritis · Psoriasis · Keratoconjunctivitis Sicca · Uveitis, Posterior · Glomerulosclerosis, Focal Segmental, led by 3 companies.
Drug pageVoclosporin: every studyAll 26 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Aurinia Pharmaceuticalsits history only | 171 open or running | phase 4since May 13, 2026 | Oct 25, 2005 | Mar 2, 2029phase 4 · NCT07611214 |
| Lux Biosciences | 50 open or running | phase 3since Nov 27, 2006 | Nov 27, 2006 | none ahead |
| Qilu Pharmaceuticalits history only | 11 open or running | phase 3since Mar 20, 2024 | Mar 20, 2024 | Jun 2027phase 3 · NCT06406205 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Lux Biosciences only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 27, 2006First studies: 3 phase 3 studiesFirst studyNCT00404885, NCT00404742, NCT00404612
- Feb 24, 2009Phase 1 study in Keratoconjunctivitis SiccaNCT00851734 · 35 enrolled · United States
- Nov 17, 2010Phase 3 study in Noninfectious UveitisNCT01243983 · 155 enrolled · United States, Austria, Brazil and more
TargetBeta
“Serine/threonine protein phosphatase 2B catalytic subunit, alpha isoform inhibitor”ChEMBL 37, by rule
Studies
All 5 Lux Biosciences leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01243983Noninfectious Uveitis · United States, Austria, Brazil and more | 3 | Completed | Dec 2012 | 155 |
| NCT00851734Keratoconjunctivitis Sicca · United States | 1 | Completed | Mar 2009 | 35 |
| NCT00404885Uveitis, Anterior · United States, Austria, Canada and more | 3 | Completed | Nov 2008 | 108 |
| NCT00404742Uveitis, Posterior · United States, Austria, Canada and more | 3 | Completed | Nov 2008 | 232 |
| NCT00404612Uveitis, Posterior · United States, Austria, Canada and more | 3 | Completed | Nov 2008 | 218 |
How it is read
Names in the registry
- “LX211”, 10 entries
- “Voclosporin”, 7 entries
- “voclosporin”, 6 entries
- “LUPKYNIS”, 1 entry
- “Voclosporin(QL1074)”, 1 entry
Conditions, from the studies’ own filings
- Lupus Nephritis, 8 studies
- Psoriasis, 3 studies
- Keratoconjunctivitis Sicca, 2 studies
- Uveitis, Posterior, 2 studies
- Glomerulosclerosis, Focal Segmental, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.